Popular Articles

First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.
buy viagra
Lobbyists Elbow For Attention As Health Reform Votes Loom
The conservative message on health care is that President Obama"s revamp of the health care system in America will produce a costly government-run program that limits patient choice, The Associated Press reports.
News of the day
Drug & Alcohol Action Team Uses SAS To Tackle Drugs And Save Lives By Improving Joined-Up Delivery
The London Borough of Croydon"s Drug & Alcohol Action Team (DAAT) is using SAS software to achieve better results in its efforts to get more people into drug treatment, reduce drug-related crime and empower the local community to resist drug misuse. SAS, the leader in business analytics software and services, gives the DAAT greater insights to commission services more effectively and target the borough"s res to where they can have the biggest impact. SAS delivers a more "joined-up" approach to allocating treatment across various agencies, which results in the most effective treatment being more quickly assigned to users who really need it.
Public Health

Skin Lesion Leads To More Cancer Types Than Once Believed

Actinic keratoses are sun-damaged rough patches or lesions on the skin - often pink and scaly - that doctors have long believed can turn into a form of skin cancer known as squamous cell carcinoma. Now researchers at Brown University, the Veterans Administration Medical Centers in Providence and Oklahoma City, and others have determined that actinic keratoses appear responsible for a larger spectrum of skin cancers than previously thought. Their research is highlighted in the current edition of Cancer. "We found some interesting things," said Dr. Martin Weinstock, the paper"s lead author. Weinstock, chief of dermatology at the VA Medical Center in Providence, is professor of dermatology and community health at The Warren Alpert Medical School of Brown University. The U.S. Department of Veterans Affairs Office of Research and Development funded the study. Vincent Criscione, a fourth-year Alpert Medical School student, served as the paper"s first author. Beyond Brown and the VA, researchers from Rhode Island Hospital and Henry Ford Hospital in Detroit also contributed. To conduct the study, Weinstock and the other researchers looked at 169 patients from the VA Medical Center in Oklahoma City who had a high risk for skin cancers. They, in turn, were among 1,131 patients from multiple cites who took part in a chemotherapy prevention trial conducted previously. Most had at least one actinic keratosis on their body. Combined, they had about 7,784 of the lesions on their faces and ears. There were up to six years of follow-up to quantify the risk of progression of actinic keratoses to cancer. Among the findings: Two-thirds of the patients who had developed squamous-cell carcinomas, a form of treatable skin cancer, could trace their cancer to actinic keratoses. One-third of patients who ended up with basal cell carcinoma, the most common form of skin cancer in the United States, could trace their cancers to actinic keratoses. Scientists had previously been able to connect squamous-cell carcinomas to the lesions, but not basal cell. They also found that the actinic keratoses come and go, becoming invisible and resurfacing over time. That was a challenge for doctors because the lesions often were not visible during follow-up. Thus, the research reinforces the need for skin cancer prevention. Scientists estimate that 40 million people in the United States alone have some form of actinic keratoses, and preventative removal of the lesions costs more than $1 billion annually, Weinstock said. Before this study, Weinstock said, scientists could rely on one other body of research conducted 20 years ago that found less than 1 in 1,000 instances of actinic keratoses annually turned into squamous cell carcinoma, even though actinic keratoses are commonly removed as a preventative treatment for skin cancer. Research is underway, Weinstock said, to determine if one of the treatments for actinic keratoses will be effective in preventing skin cancers. Mark Hollmer Brown University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):